These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 27497296)

  • 1. Oncolytic herpes simplex virus interactions with the host immune system.
    Saha D; Wakimoto H; Rabkin SD
    Curr Opin Virol; 2016 Dec; 21():26-34. PubMed ID: 27497296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncolytic herpes simplex virus and immunotherapy.
    Ma W; He H; Wang H
    BMC Immunol; 2018 Dec; 19(1):40. PubMed ID: 30563466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncolytic HSV Vectors and Anti-Tumor Immunity.
    Glorioso JC; Cohen JB; Goins WF; Hall B; Jackson JW; Kohanbash G; Amankulor N; Kaur B; Caligiuri MA; Chiocca EA; Holland EC; Quéva C
    Curr Issues Mol Biol; 2021; 41():381-468. PubMed ID: 32938804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic Virus Encoding a Master Pro-Inflammatory Cytokine Interleukin 12 in Cancer Immunotherapy.
    Nguyen HM; Guz-Montgomery K; Saha D
    Cells; 2020 Feb; 9(2):. PubMed ID: 32050597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Herpes Simplex Virus and Pattern Recognition Receptors: An Arms Race.
    Zhao J; Qin C; Liu Y; Rao Y; Feng P
    Front Immunol; 2020; 11():613799. PubMed ID: 33584700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.
    Marchini A; Scott EM; Rommelaere J
    Viruses; 2016 Jan; 8(1):. PubMed ID: 26751469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of the Intratumoral Immune Landscape by Oncolytic Herpes Simplex Virus Virotherapy.
    Yin J; Markert JM; Leavenworth JW
    Front Oncol; 2017; 7():136. PubMed ID: 28695111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells.
    Wakimoto H; Johnson PR; Knipe DM; Chiocca EA
    Gene Ther; 2003 Jun; 10(11):983-90. PubMed ID: 12756419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immune evasion by herpes simplex viruses].
    Retamal-Díaz AR; Suazo PA; Garrido I; Kalergis AM; González PA
    Rev Chilena Infectol; 2015 Feb; 32(1):58-70. PubMed ID: 25860047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic viruses and their application to cancer immunotherapy.
    Chiocca EA; Rabkin SD
    Cancer Immunol Res; 2014 Apr; 2(4):295-300. PubMed ID: 24764576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic viruses for induction of anti-tumor immunity.
    Tong AW; Senzer N; Cerullo V; Templeton NS; Hemminki A; Nemunaitis J
    Curr Pharm Biotechnol; 2012 Jul; 13(9):1750-60. PubMed ID: 21740355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PKR induces TGF-β and limits oncolytic immune therapy.
    Hong B; Sahu U; Mullarkey MP; Hong E; Pei G; Yan Y; Otani Y; Banasavadi-Siddegowda Y; Fan H; Zhao Z; Yu J; Caligiuri MA; Kaur B
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36796878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD8(+) T-cell Immune Evasion Enables Oncolytic Virus Immunotherapy.
    Pourchet A; Fuhrmann SR; Pilones KA; Demaria S; Frey AB; Mulvey M; Mohr I
    EBioMedicine; 2016 Mar; 5():59-67. PubMed ID: 27077112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic Viral Therapy and the Immune System: A Double-Edged Sword Against Cancer.
    Marelli G; Howells A; Lemoine NR; Wang Y
    Front Immunol; 2018; 9():866. PubMed ID: 29755464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic Cells in Oncolytic Virus-Based Anti-Cancer Therapy.
    Kim Y; Clements DR; Sterea AM; Jang HW; Gujar SA; Lee PW
    Viruses; 2015 Dec; 7(12):6506-25. PubMed ID: 26690204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Dilemma of HSV-1 Oncolytic Virus Delivery: The Method Choice and Hurdles.
    Tang G; Wang D; Zhao X; Feng Z; Chen Q; Shen Y
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advance in herpes simplex viruses for cancer therapy.
    Liu S; Dai M; You L; Zhao Y
    Sci China Life Sci; 2013 Apr; 56(4):298-305. PubMed ID: 23564184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evasion of host antiviral innate immunity by HSV-1, an update.
    Su C; Zhan G; Zheng C
    Virol J; 2016 Mar; 13():38. PubMed ID: 26952111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toll-like receptors as novel therapeutic targets for herpes simplex virus infection.
    Jahanban-Esfahlan R; Seidi K; Majidinia M; Karimian A; Yousefi B; Nabavi SM; Astani A; Berindan-Neagoe I; Gulei D; Fallarino F; Gargaro M; Manni G; Pirro M; Xu S; Sadeghi M; Nabavi SF; Shirooie S
    Rev Med Virol; 2019 Jul; 29(4):e2048. PubMed ID: 31265195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Innate Immune Mechanisms and Herpes Simplex Virus Infection and Disease.
    Kurt-Jones EA; Orzalli MH; Knipe DM
    Adv Anat Embryol Cell Biol; 2017; 223():49-75. PubMed ID: 28528439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.